Alnylam Pharmaceuticals, Inc.

and Jeff Fulton, Chief Financial Officer. For those of you participating in the conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.lnylam.com slash events. During today's call, as outlined in slide two, Yvonne will offer introductory remarks and provide some general context. Fogle will provide an update on our global commercial progress, which will review pipeline updates and clinical progress, and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call for your questions. I'd like to remind you that today's call will contain remarks concerning L-911's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recently periodic report on file with SEC. In addition, any forward-looking statements represent our views only as the date of this reporting and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to Yvonne. Yvonne?

Thanks, Christine, and thank you everyone for joining the call today. In the second quarter of 2023, we continue to make great progress across our business. Starting with our commercial performance, the Ambuterra launch once again drove strong growth in our TTR franchise with 46% year-over-year growth and in total product sales with 43% year-over-year growth compared to the second quarter of 2022. We also delivered strong execution across our clinical pipeline, where notable results included positive 18-month data from our Apollo B Phase III study, reaffirming the potential of paticeran in ATTR amyloidosis of cardiomyopathy. In July, we shared updated positive interim results from the phase one study of ALN-APP in patients with early onset Alzheimer's disease, showing rapid and robust target engagement with sustained effect over six months with a single dose and an encouraging clinical safety and tolerability profile. Additionally, our team executed on the business development side. Most notably, we entered into a strategic partnership with Roche for the development and commercialization of Zalbiceran, providing us with what we believe is a remarkable opportunity to bring forward a potentially transformative program with the potential to disrupt the global treatment paradigm for hypertension. We're also pleased to announce this morning that following our full cooperation with the government, the U.S. Attorney's Office for the District of Massachusetts has now concluded and closed their case regarding the marketing and promotion of On Patro in the U.S. with no action. Operating with integrity has always been and will continue to be core to our Nilem, and we will continue to hold our business conduct and, in particular, our interactions with healthcare providers and patients to the highest ethical standards. As we move into the back half of 2023, we have several important catalysts, including the initial data from our Cardia Phase II Program with Zarbisran. and pending a successful adcom and positive regulatory review, the potential launch of Onpatro and ATTR amyloidosis with cardiomyopathy. We believe all of this puts us on track with our Alnylam piece of fifth by 25 goals, making Alnylam a top tier biotech company, developing and commercializing transformative medicines for rare diseases and beyond for patients around the world, driven by a high yielding pipeline of first and all best in class product candidates from our organic product engine, all while delivering exceptional financial results. Further, before I hand the call over, I'm very pleased to share that Akshay Vajnall, our Nilem's president and key scientific leader, will be transitioning to a new and exciting role within the organization, serving as our first chief innovation officer. Akshay has been at the helm of driving science and innovation at our Nilem for nearly 18 years, and that effort has yielded an entirely new class of medicines. In his new role, Akshay will become the company's key innovation leader, focused on the future of our R&D engine, which is the lifeblood of how we have and will continue to drive our research and development programs into transformative medicines as we continue to build a top-tier biotech company. With that, let me now turn the call over to Tolga for a review of our commercial performance. Tolga?

Thanks, Yvonne, and good morning, everyone. Q2 was another strong quarter for Alnylam, driven by our TTR franchise and the strength of our ongoing launch of Amutra across several markets, which has started with the US, where it has now been available for over a year. Our total net product revenues across all products grew 43% year over year in Q2. Let me now review our TTR performance during Q2. The TTR franchise achieved $224 million in global net product revenues for Onpatro and Ambutra, representing a 9% increase compared with the first quarter and 46% growth compared with the second quarter of 2022. At the end of the second quarter, over 3,490 patients were on Onpatro or Ambutra treatment worldwide, up from over 3,160 patients at the end of the first quarter, representing 10% quarterly patient growth. With respect to our international performance, total TTR second quarter product sales increased 6% versus the first quarter, driven by strong ombudsman demand in Japan and the UK, UK being our most recent launch market. After more than six months since its launch, the Amutra demand growth in Japan is particularly encouraging, with new patient growth being driven by a mix of switches from tefamidus as well as patients naive to therapy. Importantly, Onpatra continues to deliver steady growth in markets where Amutra is not yet available, a sign of our robust demand generation activities as we position these markets for upcoming Ambutra launches. Now, let me turn to the U.S., where combined sales of Ampatro and Ambutra increased by 12% versus the first quarter, and Eroba's 72% year-over-year growth, representing the fourth consecutive quarter of achieving TTR growth in excess of 70% on a year-over-year basis in the U.S., since the launch of Ambutra in the third quarter of 2022. This significant growth was primarily driven by a 15% increase in demand, which more than offset the decrease in patients on Onpatro that switched to Ambutra, and the robust demand was slightly offset by inventory dynamics, which decreased reported growth by approximately 2%, with channel inventory reductions to both products. Amutra continues to expand the overall TTR polyneuropathy franchise as reflected by our year-over-year growth. The steady growth of Amutra performance in the U.S. is a testament to the significant unmet need of patients with TTR polyneuropathy, our commercial capabilities, and naturally the product profile of Amutra. Our leading performance indicators also continue to trend favorably, including the expansion of our prescriber base, and favorable access, resulting in patient compliance rates of over 90%. A year into launch, we have increased our prescriber base by almost 50% through a balanced mix of academic centers and community-based specialists, while switching a majority of the patients who are on PATRA at the time of our neutral launch. Now, update on our ultra-rare franchise. We are proud to have developed and commercialized two ultra-rare products, transforming small patient populations that suffer greatly. Givlar and Oxluma together delivered $82 million in combined product sales during the second quarter, representing a 14% increase compared with the first quarter and a solid 37% growth compared with the second quarter of 2022. We ended the quarter with more than 570 patients on Givlari commercial therapy and more than 350 patients on Oxlomo commercial therapy, representing 8% combined quarterly growth in patients on our ultra-rare products compared with the first quarter of 2023. For Givlari, global revenue growth of 21% in Q2 compared the first quarter was driven by the following. In the U.S., we had an increase in the number of patients on therapy and an increase in patient compliance rates. A robust 29% in our international markets, which was impacted positively, both by demand growth as well as order timing in our partner markets. For Oksumo, flat quarterly revenue was a result of Fewer US patients on a loading dose regimen, which offset modest patient growth. Growth in international markets was primarily driven by order timing in partner markets, which was partially offset by an unfavorable pricing mix in our European markets. Overall, Q223 was another quarter of healthy growth in revenues in our quest to serve more patients. With over a year since launch, We are particularly pleased with the steady growth of Amutra, which represents an important therapy option for HATTR amniotis patients with polyneuropathy. With that, I will now turn it over to Pushkal to review our recent R&D and pipeline progress. Pushkal?